1,855.30
+3.07%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aurobindo Pharma
Its shares trade on NSE under the ticker AUROPHARMA.NS. It has been listed since 19 January 1995. In the fiscal year to 31 March 2026, it reported revenue of ₹336.53bn and net income of ₹35.05bn. At that date it held total assets of ₹585.02bn and shareholders' equity of ₹378.91bn.
Aurobindo Pharma Ltd. engages in the manufacturing of generic pharmaceuticals and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The firm develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. Its product portfolio is spread over seven therapeutic/product areas encompassing central nervous systems (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-allergic. The company is engaged in developing a range of oncology and hormonal products. The company is developing topical as well as transdermal products in the dermatology therapeutic segment. The company is also developing about three depot injections based on the microsphere and nano-suspension technology platforms. The firm is marketing its products globally in approximately 150 countries. The firm's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited and Aurolife Pharma LLC, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Jan 1995
- Employees
- 21,000
- Website
- aurobindo.com ↗
Leadership
Pay as last reported
- Shri. Mangalam KumarNon-Executive Independent Chairman of the Board₹2.0m
- Mr. Kambam ReddyExecutive Vice Chairman of the Board, Managing Director, Promoter, since 2022₹54.7m
- Mr. Santhanam SubramanianChief Financial Officer₹48.6m
- Mr. B. Adi ReddyCompliance Officer, Company Secretary, since 2024₹9.0m
- Mr. Mettu Madan ReddyWhole-Time Director, since 2006₹69.8m
- Dr. Satakarni MakkapatiNon-Executive Non-Independent Director₹300,000
- Mr. Penaka Sarath ReddyNon-Executive Non-Independent Director, since 2007₹900,000
- Mr. Penaka Venkata ReddyNon-Executive Director, Promoter, since 2012₹600,000
- Dr. Deepali JoshiNon-Executive Independent Director₹2.0m
- Mr. Santanu MukerjeeNon-Executive Independent Director₹2.0m
- Dr. Punita SinhaAdditional Non-Executive Independent Director
- Mr. Girish VanvariNon-Executive Independent Director₹2.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 58
- Environment
- 58
- Social
- 73
- Governance
- 42
- Direct emissions (scope 1)
- 414,356 t
- Energy emissions (scope 2)
- 553,115 t
- Women in the workforce
- 13%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong market position: Aurobindo Pharma Ltd has achieved a solid market position in the pharmaceutical industry.
- Diversified product portfolio: The company offers a wide range of products in various therapeutic segments, which helps reduce dependence on a single product category.
- Robust manufacturing capabilities: Aurobindo Pharma has established efficient manufacturing facilities, allowing for cost-effective production and timely delivery of products.
- Extensive global presence: The company has a widespread international footprint, operating across multiple geographies, which helps in revenue diversification and potential growth opportunities.
Weaknesses
- Quality control challenges: Aurobindo Pharma has faced certain quality control issues in the past, which have impacted its brand reputation and may lead to regulatory scrutiny.
- Overdependence on few key markets: The company heavily relies on a small number of markets for a significant portion of its revenue, making it vulnerable to market-specific risks.
- Limited pipeline of novel drugs: Aurobindo Pharma's focus has been primarily on generic drugs, lacking a substantial pipeline of breakthrough innovative medicines for future growth.
Opportunities
- Increasing generic drug demand: The growing preference for generic medications presents an opportunity for Aurobindo Pharma to expand its market share and revenue.
- Expansion into emerging markets: The company can explore untapped markets in developing countries, where there is a rising need for affordable healthcare solutions.
- Strategic partnerships and acquisitions: Aurobindo Pharma can pursue collaborations or acquisitions to access new technologies, strengthen its product portfolio, or enter new markets.
Threats
- Intense competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share, which could lead to pricing pressures and reduced profitability.
- Stringent regulatory requirements: Compliance with stringent regulations in various countries can pose challenges and increase costs for Aurobindo Pharma.
- Intellectual property rights issues: The company may face legal disputes or delays in product launches due to patent infringement allegations or licensing complications.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.